This is the authors' abstract. We don't add key points for this paper.
This editorial describes, and puts into context, the statement on M/XDR-TB written by the TBNET Group http://ow.ly/wFoxrThe good news about tuberculosis (TB) is that in the 29 reporting European Union/European Economic Area countries the number of incident TB cases is falling, with an average annual decline of 6% since 2011 [1].The bad news is that, however you look at it, multidrug-resistant TB (MDR-TB) and extensively drugresistant TB (XDR-TB) remain a major clinical and public health problem worldwide, particularly in former Soviet Union countries and Central Asia [2][3][4].Less than a quarter of the total estimated MDR-TB cases were actually diagnosed in 2012 [2], with dramatic consequences from an individual and a community perspective (i.e.increased morbidity, mortality and drug-resistant Mycobacterium tuberculosis transmission).It was estimated that 450 000 incident patients developed MDR-TB and 170 000 died from MDR-TB.More than half of such cases die, fail or stop taking treatment and only one in three cases in reporting countries completes the long treatment course (.20 months).The treatment success in the 2010 MDR-TB cohort was 48%, only 34 (31.8%)out of 107 countries reached a therapeutic success rate of at least 75%.About 9.6% of the MDR-TB cohort was XDR-TB.The direct and indirect costs are significant from a healthcare and a societal perspective [5,6].While the cost per case for drug-susceptible TB is estimated to be ,J10 000, that for MDR-TB and for XDR-TB is estimated to be ,J50 000 and J170 000, respectively [5].The reasons for this increased cost are fairly obvious since successful management often requires a prolonged inpatient stay, exposure to a cocktail of multiple, expensive, usually less effective medications with frequent serious and unpleasant toxicities, to be taken under close medical and/or social supervision for many months (so-called directly observed therapy).That a significant proportion of initially drugsusceptible TB can become MDR during treatment, following poor patient adherence mainly caused by drug toxicity and long treatment duration, is also a concern [7][8][9].Case management is not helped by the geographical distribution of TB patients across countries.For instance, of the 54 World Health Organization (WHO) European Region countries reporting 33 371 cases of MDR-TB in 2012, five reported more than 1 000 individuals with TB annually (Belarus, Kazakhstan, Russia, Ukraine and Uzbekistan), while 20 countries reported less than 10 individuals annually.Clinical experience in MDR-TB management is thus concentrated in few, sometimes poorly resourced countries, whereas cases are thinly spread across other better resourced countries.Guidance on MDR-TB management is, therefore, welcome to most healthcare workers involved in TB patient care and the consensus statement produced by the Tuberculosis Network European Trials Group (TBNET) group in this issue of the European Respiratory Journal delivers exactly what is needed [10].
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Sotgiu et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: